Neriman Gokden
Concepts (357)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 13 | 2021 | 182 | 2.520 |
Why?
| | Carcinoma, Renal Cell | 13 | 2021 | 111 | 2.200 |
Why?
| | Kidney Diseases | 8 | 2020 | 220 | 1.120 |
Why?
| | Immunohistochemistry | 14 | 2021 | 979 | 1.090 |
Why?
| | Kidney | 15 | 2025 | 707 | 1.050 |
Why?
| | PAX2 Transcription Factor | 4 | 2010 | 24 | 1.020 |
Why?
| | Kidney Tubules | 7 | 2021 | 62 | 1.000 |
Why?
| | Immunoglobulin Light Chains | 4 | 2017 | 90 | 0.770 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2020 | 2 | 0.690 |
Why?
| | Rhabdoid Tumor | 1 | 2020 | 13 | 0.690 |
Why?
| | Stromal Cells | 1 | 2020 | 79 | 0.670 |
Why?
| | Soft Tissue Neoplasms | 1 | 2020 | 57 | 0.650 |
Why?
| | Acute Kidney Injury | 8 | 2025 | 319 | 0.630 |
Why?
| | Immune Complex Diseases | 2 | 2008 | 6 | 0.560 |
Why?
| | Sepsis | 7 | 2014 | 239 | 0.530 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2008 | 155 | 0.490 |
Why?
| | Adenoma | 2 | 2021 | 113 | 0.430 |
Why?
| | Adenoma, Oxyphilic | 2 | 2010 | 11 | 0.420 |
Why?
| | Carcinoma, Papillary | 2 | 2010 | 51 | 0.410 |
Why?
| | Male | 38 | 2025 | 26761 | 0.390 |
Why?
| | Renal Circulation | 5 | 2013 | 56 | 0.370 |
Why?
| | Middle Aged | 26 | 2025 | 13028 | 0.370 |
Why?
| | Prostatic Neoplasms | 5 | 2010 | 398 | 0.370 |
Why?
| | Proteinuria | 2 | 2010 | 39 | 0.360 |
Why?
| | Glomerulonephritis, IGA | 1 | 2010 | 4 | 0.350 |
Why?
| | Humans | 44 | 2025 | 52483 | 0.350 |
Why?
| | Podocytes | 1 | 2010 | 18 | 0.350 |
Why?
| | Microcirculation | 5 | 2014 | 64 | 0.340 |
Why?
| | Nephrectomy | 2 | 2010 | 82 | 0.340 |
Why?
| | Antigens, Neoplasm | 2 | 2008 | 147 | 0.330 |
Why?
| | Microscopy, Electron, Transmission | 5 | 2014 | 78 | 0.330 |
Why?
| | Neurofibromatosis 2 | 1 | 2009 | 7 | 0.320 |
Why?
| | DNA Glycosylases | 1 | 2008 | 19 | 0.300 |
Why?
| | Adult | 19 | 2023 | 14161 | 0.290 |
Why?
| | Female | 26 | 2025 | 28171 | 0.290 |
Why?
| | Lymph Nodes | 1 | 2010 | 258 | 0.290 |
Why?
| | Renal Insufficiency | 4 | 2013 | 113 | 0.290 |
Why?
| | Plasmacytoma | 2 | 2020 | 43 | 0.290 |
Why?
| | Kidney Glomerulus | 1 | 2008 | 41 | 0.280 |
Why?
| | Hypercalcemia | 1 | 2007 | 34 | 0.270 |
Why?
| | Diagnosis, Differential | 6 | 2021 | 1046 | 0.270 |
Why?
| | DNA Repair | 1 | 2008 | 195 | 0.270 |
Why?
| | Alphapapillomavirus | 1 | 2006 | 13 | 0.260 |
Why?
| | Sensitivity and Specificity | 5 | 2011 | 891 | 0.260 |
Why?
| | Predictive Value of Tests | 6 | 2025 | 944 | 0.260 |
Why?
| | Carcinoma | 2 | 2020 | 138 | 0.260 |
Why?
| | Bone Density Conservation Agents | 1 | 2007 | 75 | 0.260 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 62 | 0.260 |
Why?
| | Hepatitis B | 1 | 2006 | 16 | 0.260 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2006 | 15 | 0.260 |
Why?
| | Diphosphonates | 1 | 2007 | 92 | 0.260 |
Why?
| | Imidazoles | 1 | 2007 | 124 | 0.250 |
Why?
| | DNA, Viral | 1 | 2006 | 137 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2014 | 165 | 0.250 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2005 | 8 | 0.250 |
Why?
| | Biopsy | 6 | 2020 | 605 | 0.240 |
Why?
| | Adenocarcinoma | 2 | 2010 | 405 | 0.240 |
Why?
| | Skin Neoplasms | 2 | 2018 | 505 | 0.240 |
Why?
| | Cisplatin | 4 | 2025 | 285 | 0.240 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 1 | 2025 | 17 | 0.230 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2005 | 44 | 0.230 |
Why?
| | Aged | 14 | 2025 | 10121 | 0.220 |
Why?
| | Metformin | 1 | 2025 | 76 | 0.220 |
Why?
| | Paraproteinemias | 2 | 2016 | 74 | 0.210 |
Why?
| | Pheochromocytoma | 1 | 2023 | 35 | 0.210 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2023 | 49 | 0.210 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 211 | 0.210 |
Why?
| | Aged, 80 and over | 8 | 2017 | 3392 | 0.210 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2024 | 117 | 0.210 |
Why?
| | Dermatofibrosarcoma | 1 | 2003 | 9 | 0.200 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2003 | 61 | 0.200 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 187 | 0.190 |
Why?
| | Kidney Transplantation | 1 | 2024 | 192 | 0.190 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 18 | 0.180 |
Why?
| | Immunoglobulin G | 2 | 2014 | 195 | 0.180 |
Why?
| | Multiple Myeloma | 3 | 2017 | 3049 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2021 | 85 | 0.170 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2012 | 54 | 0.170 |
Why?
| | Qb-SNARE Proteins | 1 | 2019 | 6 | 0.170 |
Why?
| | Qc-SNARE Proteins | 1 | 2019 | 10 | 0.160 |
Why?
| | Actin Cytoskeleton | 1 | 2019 | 22 | 0.160 |
Why?
| | Hepatic Stellate Cells | 1 | 2019 | 18 | 0.160 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2020 | 37 | 0.160 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 1222 | 0.160 |
Why?
| | Myofibroblasts | 1 | 2019 | 50 | 0.160 |
Why?
| | Animals | 16 | 2025 | 13505 | 0.160 |
Why?
| | Retrospective Studies | 6 | 2025 | 6607 | 0.160 |
Why?
| | Cell Nucleus | 2 | 2010 | 187 | 0.150 |
Why?
| | Neoplasm Metastasis | 2 | 2010 | 243 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2021 | 210 | 0.150 |
Why?
| | Mice | 12 | 2025 | 5949 | 0.150 |
Why?
| | Myoblasts | 1 | 2018 | 19 | 0.140 |
Why?
| | Melanoma | 2 | 2018 | 288 | 0.140 |
Why?
| | Synovitis | 1 | 2017 | 20 | 0.140 |
Why?
| | Capillaries | 4 | 2014 | 50 | 0.140 |
Why?
| | Eosinophilia | 1 | 2017 | 36 | 0.130 |
Why?
| | Cell Proliferation | 1 | 2021 | 1023 | 0.130 |
Why?
| | DNA, Neoplasm | 3 | 2008 | 146 | 0.130 |
Why?
| | Obesity | 1 | 2025 | 1162 | 0.130 |
Why?
| | Angiomyolipoma | 1 | 2016 | 10 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2025 | 1478 | 0.130 |
Why?
| | Thoracic Neoplasms | 1 | 2016 | 13 | 0.130 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 39 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 130 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 236 | 0.120 |
Why?
| | Receptors, Lysosphingolipid | 1 | 2014 | 7 | 0.120 |
Why?
| | Reactive Nitrogen Species | 3 | 2011 | 23 | 0.120 |
Why?
| | Urothelium | 1 | 2014 | 19 | 0.110 |
Why?
| | Hemangiosarcoma | 1 | 2014 | 15 | 0.110 |
Why?
| | Mice, Inbred C57BL | 6 | 2025 | 1884 | 0.110 |
Why?
| | Neoplasm Staging | 3 | 2014 | 772 | 0.110 |
Why?
| | Oxidative Stress | 2 | 2025 | 807 | 0.110 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2014 | 22 | 0.110 |
Why?
| | Necrosis | 2 | 2012 | 176 | 0.110 |
Why?
| | Glomerulonephritis, Membranous | 1 | 2014 | 28 | 0.110 |
Why?
| | Rolipram | 1 | 2013 | 2 | 0.110 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2013 | 4 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 133 | 0.110 |
Why?
| | Microscopy, Electron | 2 | 2020 | 75 | 0.110 |
Why?
| | Glomerular Filtration Rate | 4 | 2017 | 124 | 0.100 |
Why?
| | Translocation, Genetic | 2 | 2005 | 265 | 0.100 |
Why?
| | Organ Preservation | 2 | 2024 | 32 | 0.100 |
Why?
| | Sarcoidosis | 1 | 2013 | 44 | 0.100 |
Why?
| | Prospective Studies | 2 | 2010 | 2481 | 0.100 |
Why?
| | Livedo Reticularis | 1 | 2012 | 5 | 0.100 |
Why?
| | Cryoglobulinemia | 1 | 2012 | 13 | 0.100 |
Why?
| | Lipoprotein Lipase | 1 | 2012 | 14 | 0.100 |
Why?
| | DNA, Mitochondrial | 2 | 2003 | 114 | 0.100 |
Why?
| | Metalloporphyrins | 1 | 2011 | 6 | 0.090 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 25 | 0.090 |
Why?
| | Cellular Microenvironment | 1 | 2011 | 30 | 0.090 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2011 | 5 | 0.090 |
Why?
| | Myocardium | 2 | 2017 | 453 | 0.090 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 461 | 0.090 |
Why?
| | Triglycerides | 1 | 2012 | 165 | 0.090 |
Why?
| | Stilbenes | 1 | 2011 | 58 | 0.090 |
Why?
| | Tissue Array Analysis | 2 | 2011 | 46 | 0.090 |
Why?
| | Microscopy, Fluorescence | 2 | 2014 | 160 | 0.090 |
Why?
| | Rats | 3 | 2025 | 3220 | 0.090 |
Why?
| | Peritoneal Neoplasms | 1 | 2012 | 65 | 0.090 |
Why?
| | Metalloendopeptidases | 1 | 2011 | 69 | 0.090 |
Why?
| | Hematuria | 1 | 2010 | 26 | 0.090 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 111 | 0.090 |
Why?
| | Ejaculatory Ducts | 1 | 2010 | 3 | 0.090 |
Why?
| | Seminal Vesicles | 1 | 2010 | 13 | 0.080 |
Why?
| | Plasma Cells | 1 | 2012 | 239 | 0.080 |
Why?
| | In Situ Hybridization | 2 | 2006 | 64 | 0.080 |
Why?
| | Hemodynamics | 1 | 2011 | 263 | 0.080 |
Why?
| | RNA, Messenger | 4 | 2012 | 1132 | 0.080 |
Why?
| | Antioxidants | 1 | 2011 | 256 | 0.080 |
Why?
| | Prostate | 1 | 2010 | 116 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2011 | 215 | 0.080 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 220 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2009 | 197 | 0.080 |
Why?
| | Survival Analysis | 3 | 2017 | 673 | 0.080 |
Why?
| | Iron Chelating Agents | 1 | 2008 | 12 | 0.080 |
Why?
| | Ligation | 3 | 2014 | 60 | 0.080 |
Why?
| | Nephritis, Interstitial | 1 | 2008 | 9 | 0.070 |
Why?
| | Benzoates | 1 | 2008 | 21 | 0.070 |
Why?
| | Microsatellite Repeats | 1 | 2008 | 42 | 0.070 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2008 | 3 | 0.070 |
Why?
| | Glomerular Mesangium | 1 | 2008 | 7 | 0.070 |
Why?
| | Loss of Heterozygosity | 1 | 2008 | 78 | 0.070 |
Why?
| | Basement Membrane | 1 | 2008 | 18 | 0.070 |
Why?
| | Triazoles | 1 | 2008 | 115 | 0.070 |
Why?
| | Cell Membrane | 1 | 2008 | 245 | 0.070 |
Why?
| | Disease Progression | 2 | 2025 | 871 | 0.070 |
Why?
| | Glomerular Basement Membrane | 1 | 2007 | 10 | 0.070 |
Why?
| | Mutation | 2 | 2003 | 1347 | 0.070 |
Why?
| | Kidney Pelvis | 1 | 2006 | 16 | 0.070 |
Why?
| | Prednisone | 1 | 2007 | 102 | 0.070 |
Why?
| | Paraffin Embedding | 1 | 2006 | 52 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 399 | 0.070 |
Why?
| | Karyotyping | 3 | 2017 | 78 | 0.060 |
Why?
| | Heart Diseases | 1 | 2009 | 216 | 0.060 |
Why?
| | Prognosis | 2 | 2025 | 2099 | 0.060 |
Why?
| | Nephrotic Syndrome | 1 | 2006 | 19 | 0.060 |
Why?
| | Young Adult | 4 | 2021 | 4329 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2025 | 879 | 0.060 |
Why?
| | Clofibric Acid | 1 | 2005 | 7 | 0.060 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2005 | 25 | 0.060 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2005 | 30 | 0.060 |
Why?
| | Rats, Zucker | 1 | 2025 | 73 | 0.060 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 69 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 206 | 0.060 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2005 | 17 | 0.060 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2005 | 20 | 0.060 |
Why?
| | Neurofibroma | 1 | 2005 | 16 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2007 | 235 | 0.060 |
Why?
| | Foot | 1 | 2005 | 41 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 807 | 0.060 |
Why?
| | Fibroma | 1 | 2005 | 40 | 0.060 |
Why?
| | Blood Pressure | 3 | 2011 | 537 | 0.060 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2004 | 16 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2005 | 183 | 0.060 |
Why?
| | Endodeoxyribonucleases | 1 | 2004 | 44 | 0.060 |
Why?
| | Administration, Oral | 1 | 2025 | 451 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 122 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2023 | 31 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2023 | 39 | 0.050 |
Why?
| | Groin | 1 | 2003 | 16 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2004 | 179 | 0.050 |
Why?
| | Vulva | 1 | 2003 | 18 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2024 | 104 | 0.050 |
Why?
| | RNA, Neoplasm | 1 | 2003 | 45 | 0.050 |
Why?
| | Time Factors | 3 | 2014 | 2968 | 0.050 |
Why?
| | Micromanipulation | 1 | 2002 | 2 | 0.050 |
Why?
| | Cytoplasm | 1 | 2003 | 94 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 137 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2003 | 107 | 0.050 |
Why?
| | Blotting, Western | 3 | 2012 | 590 | 0.050 |
Why?
| | Perfusion | 1 | 2002 | 48 | 0.050 |
Why?
| | Sodium Chloride | 1 | 2002 | 56 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 278 | 0.050 |
Why?
| | Blood Flow Velocity | 2 | 2013 | 95 | 0.050 |
Why?
| | Hypothermia, Induced | 1 | 2002 | 40 | 0.050 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 229 | 0.050 |
Why?
| | Mass Screening | 1 | 2005 | 357 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 582 | 0.050 |
Why?
| | Capillary Permeability | 2 | 2011 | 27 | 0.050 |
Why?
| | Cardiac Surgical Procedures | 1 | 2025 | 321 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2025 | 1026 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 2003 | 184 | 0.040 |
Why?
| | Adolescent | 3 | 2014 | 6739 | 0.040 |
Why?
| | Hyperplasia | 1 | 2021 | 98 | 0.040 |
Why?
| | Inflammation | 1 | 2025 | 641 | 0.040 |
Why?
| | Transcription Factors | 1 | 2004 | 566 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2014 | 665 | 0.040 |
Why?
| | Liver | 2 | 2019 | 1156 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 28 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 263 | 0.040 |
Why?
| | Heart Rate | 2 | 2011 | 318 | 0.040 |
Why?
| | Stress Fibers | 1 | 2019 | 5 | 0.040 |
Why?
| | Actin Depolymerizing Factors | 1 | 2019 | 5 | 0.040 |
Why?
| | rho-Associated Kinases | 1 | 2019 | 18 | 0.040 |
Why?
| | Carbon Tetrachloride | 1 | 2019 | 25 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2017 | 5422 | 0.040 |
Why?
| | RNA, Viral | 1 | 2020 | 127 | 0.040 |
Why?
| | Cell Separation | 1 | 2019 | 83 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 108 | 0.040 |
Why?
| | Nitrites | 2 | 2011 | 31 | 0.040 |
Why?
| | Nitrates | 2 | 2011 | 31 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2003 | 333 | 0.040 |
Why?
| | Child, Preschool | 2 | 2011 | 4076 | 0.040 |
Why?
| | Neutrophil Infiltration | 2 | 2012 | 24 | 0.040 |
Why?
| | RNA Interference | 1 | 2019 | 181 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 213 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 481 | 0.040 |
Why?
| | Actins | 1 | 2019 | 115 | 0.040 |
Why?
| | Cecum | 2 | 2011 | 61 | 0.040 |
Why?
| | Cell Movement | 1 | 2019 | 268 | 0.040 |
Why?
| | Cell Dedifferentiation | 1 | 2018 | 9 | 0.040 |
Why?
| | Wound Healing | 1 | 2019 | 219 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2011 | 421 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 54 | 0.030 |
Why?
| | Microscopy, Video | 2 | 2007 | 13 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 240 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 62 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 1030 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2003 | 636 | 0.030 |
Why?
| | Acute Disease | 2 | 2008 | 373 | 0.030 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2016 | 5 | 0.030 |
Why?
| | Risk Factors | 1 | 2005 | 3889 | 0.030 |
Why?
| | Genomics | 1 | 2017 | 268 | 0.030 |
Why?
| | Cysts | 1 | 2016 | 51 | 0.030 |
Why?
| | Bone Marrow | 1 | 2017 | 364 | 0.030 |
Why?
| | Immunotherapy | 1 | 2017 | 244 | 0.030 |
Why?
| | Oxadiazoles | 1 | 2014 | 9 | 0.030 |
Why?
| | Permeability | 1 | 2014 | 66 | 0.030 |
Why?
| | Punctures | 1 | 2014 | 52 | 0.030 |
Why?
| | Thiophenes | 1 | 2014 | 38 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 2014 | 35 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2014 | 70 | 0.030 |
Why?
| | Pyrazoles | 1 | 2014 | 114 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 78 | 0.030 |
Why?
| | Pyridines | 1 | 2014 | 132 | 0.030 |
Why?
| | Granuloma | 1 | 2013 | 47 | 0.030 |
Why?
| | Signal Transduction | 1 | 2019 | 1671 | 0.020 |
Why?
| | Bone Marrow Examination | 1 | 2012 | 11 | 0.020 |
Why?
| | Receptors, Lipoprotein | 1 | 2012 | 7 | 0.020 |
Why?
| | Azo Compounds | 1 | 2012 | 11 | 0.020 |
Why?
| | Angiopoietins | 1 | 2012 | 5 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 15 | 0.020 |
Why?
| | Plasma Exchange | 1 | 2012 | 25 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 69 | 0.020 |
Why?
| | Adipose Tissue, White | 1 | 2012 | 35 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 243 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 65 | 0.020 |
Why?
| | Cystectomy | 1 | 2012 | 51 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 83 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2011 | 119 | 0.020 |
Why?
| | Telemetry | 1 | 2011 | 29 | 0.020 |
Why?
| | Peritonitis | 1 | 2011 | 27 | 0.020 |
Why?
| | Child | 2 | 2016 | 7248 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1378 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2011 | 49 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2011 | 96 | 0.020 |
Why?
| | Hydroxamic Acids | 1 | 2011 | 38 | 0.020 |
Why?
| | Hypothermia | 1 | 2011 | 36 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2011 | 78 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2011 | 326 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 86 | 0.020 |
Why?
| | United States | 1 | 2021 | 5192 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 523 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 362 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2012 | 335 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 618 | 0.020 |
Why?
| | Skin | 1 | 2012 | 422 | 0.020 |
Why?
| | Iron Overload | 1 | 2008 | 9 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 2867 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2012 | 1567 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 52 | 0.020 |
Why?
| | Eosinophils | 1 | 2008 | 44 | 0.020 |
Why?
| | Drug Hypersensitivity | 1 | 2008 | 39 | 0.020 |
Why?
| | Myelodysplastic Syndromes | 1 | 2008 | 86 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 1563 | 0.020 |
Why?
| | NADP | 1 | 2006 | 22 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2006 | 42 | 0.020 |
Why?
| | Lysine | 1 | 2007 | 89 | 0.020 |
Why?
| | Creatinine | 1 | 2006 | 150 | 0.020 |
Why?
| | Nuclease Protection Assays | 1 | 2005 | 2 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2005 | 7 | 0.020 |
Why?
| | Receptors, CCR1 | 1 | 2005 | 10 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2005 | 9 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 12 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 249 | 0.010 |
Why?
| | Stress, Physiological | 1 | 2006 | 183 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2005 | 74 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2005 | 61 | 0.010 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 39 | 0.010 |
Why?
| | Muscle Neoplasms | 1 | 2005 | 16 | 0.010 |
Why?
| | Chemokines | 1 | 2005 | 79 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 372 | 0.010 |
Why?
| | PPAR alpha | 1 | 2005 | 59 | 0.010 |
Why?
| | Prostatectomy | 1 | 2005 | 84 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 235 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 154 | 0.010 |
Why?
| | Kidney Tubules, Proximal | 1 | 2004 | 61 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 67 | 0.010 |
Why?
| | Ligands | 1 | 2004 | 206 | 0.010 |
Why?
| | Cell Death | 1 | 2004 | 177 | 0.010 |
Why?
| | Pyrimidines | 1 | 2005 | 199 | 0.010 |
Why?
| | Antigens, CD | 1 | 2005 | 218 | 0.010 |
Why?
| | NF-kappa B | 1 | 2005 | 322 | 0.010 |
Why?
| | Models, Genetic | 1 | 2003 | 169 | 0.010 |
Why?
| | Multigene Family | 1 | 2002 | 48 | 0.010 |
Why?
| | Infant | 1 | 2011 | 3733 | 0.010 |
Why?
| | Renal Artery Obstruction | 1 | 2002 | 21 | 0.010 |
Why?
| | Lasers | 1 | 2002 | 108 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 640 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2002 | 185 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 623 | 0.010 |
Why?
| | Models, Animal | 1 | 2002 | 234 | 0.010 |
Why?
| | Ischemia | 1 | 2002 | 150 | 0.010 |
Why?
| | Swine | 1 | 2002 | 428 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 406 | 0.010 |
Why?
| | Laparoscopy | 1 | 2002 | 180 | 0.010 |
Why?
|
|
Gokden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|